Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Salbutamol with HFA-152a vs HFA-134a Propellants
NCT05791565Phase 1Completed
- Sponsor
- GSK
- Start
- Apr 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of salbutamol in asthma (2 arms), sponsored by GSK. Primary endpoints: Area Under the Plasma Concentration-time Curve up to 30 Minutes Post-dose, Area Under the Plasma Concentration-time Curve from Time 0 to Infinity at Day 4 and 2 more. Started Apr 2023; status: completed.
02
Drugs
salbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05791565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05791565.